Vantictumab: Phase Ib data
Top-line data from 21 evaluable patients with locally recurrent or metastatic HER2-negative breast cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab plus paclitaxel led to 7 partial responses and 6 cases of stable disease. Vantictumab was well tolerated with fatigue, constipation, diarrhea, nausea and abdominal pain reported as the most common treatment-related adverse events. Patients received 3.5, 7 or 14 mg/kg IV vantictumab every 2 weeks plus paclitaxel. After 2 grade 2 fragility fractures were observed, 12 patients were treated under a revised safety plan with 3 or 5 mg/kg IV vantictumab every 4 weeks plus paclitaxel. Data will be presented at the American Society of Clinical Oncology meeting in Chicago (see BioCentury, June 16, 2014 & Sept. 1, 2014). ...